Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6386434 | 0.82 | HDAC1 (0.65) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL5283814 | 0.79 | LMNA (0.53) | ALDH1A1 | |
| SCHEMBL2792417 | 0.78 | ALDH1A1 (0.59) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL30424999 | 0.78 | ALDH1A1 (0.59) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL4419588 | 0.78 | ALDH1A1 (0.49) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL6706804 | 0.77 | ALDH1A1 (0.70) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL287420 | 0.76 | ALDH1A1 (0.74) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL27768646 | 0.76 | ALDH1A1 (0.74) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL17206253 | 0.76 | ALDH1A1 (0.56) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL5290844 | 0.74 | MAPT (0.61) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | ALDH1A1 2972/4885HDAC1 2670/4885HDAC8 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.